CLL cells also require intact BTK function to home and adhere to lymphoid organs[87,88], leading to peripheralization of malignant cells with ibrutinib treatment and deprivation of microenvironment survival signalling[89]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.